MedTrace Logo

Blinatumomab for Treatment of Refractory Myasthenia Gravis

NCT06836973 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-03-25

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are:

* Does Blinatumomab improve patients' clinical symptoms?
* Is Blinatumomab safe for the treatment of myasthenia gravis?

Participants will:

* Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles.
* Visit the clinic once every 4 weeks for checkups and tests.
* Keep a diary of their symptoms and the types and dosages of medications.

Conditions

Interventions

DRUG

Blinatumomab

Blinatumomab is used at its starting dose of 9 µg per day and administered as continuous infusion for 5 days (total dose of 38.5 µg). After a 1-week pause, the patients receive a second 5-day infusion with blinatumomab of total 38.5 µg of the drug.

Sponsors & Collaborators

  • Da, Yuwei, M.D.

    lead INDIV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2028-03-31
Completion
2028-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06836973 on ClinicalTrials.gov